血型基因型配合性输血的临床研究

注册号:

Registration number:

ChiCTR1800015750 

最近更新日期:

Date of Last Refreshed on:

2018-04-18 20:32:09 

注册时间:

Date of Registration:

2018-04-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

血型基因型配合性输血的临床研究

Public title:

Clinical study of blood group genotype-matched transfusion

注册题目简写:

English Acronym:

研究课题的正式科学名称:

血型基因型配合性输血的临床研究

Scientific title:

Clinical study of blood group genotype-matched transfusion

研究课题代号(代码):

Study subject ID:

BE2017757

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张若洋 

研究负责人:

梁文飚 

Applicant:

Ruoyang ZHANG 

Study leader:

Wenbiao LIANG 

申请注册联系人电话:

Applicant telephone:

+86 13032557316

研究负责人电话:

Study leader's
telephone:

+86 18913826070

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

cdkey4567@163.com

研究负责人电子邮件:

Study leader's E-mail:

thibaut@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

南京市龙蟠路179号

研究负责人通讯地址:

南京市龙蟠路179号

Applicant address:

179 Longpan Road, Nanjing, China

Study leader's address:

179 Longpan Road, Nanjing, China

申请注册联系人邮政编码:

Applicant postcode:

210042

研究负责人邮政编码:

Study leader's postcode:

210042

申请人所在单位:

江苏省血液中心

Applicant's institution:

Jiangsu Province Blood Center

研究负责人所在单位:

江苏省血液中心

Affiliation of the Leader:

Jiangsu Province Blood Center

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20180312

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

江苏省血液中心医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Jiangsu Province Blood Center

伦理委员会批准日期:

Date of approved by ethic committee:

2018-03-12 00:00:00

伦理委员会联系人:

陈妍

Contact Name of the ethic committee:

Yan CHEN

伦理委员会联系地址:

南京市龙蟠路179号

Contact Address of the ethic committee:

179 Longpan Road, Nanjing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省血液中心

Primary sponsor:

Jiangsu Province Blood Center

研究实施负责(组长)单位地址:

南京市龙蟠路179号

Primary sponsor's address:

179 Longpan Road, Nanjing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

江苏省人民医院

具体地址:

南京市广州路300号

Institution
hospital:

Jiangsu Province Hospital

Address:

300 Guangzhou Road, Nanjing

经费或物资来源:

江苏省科技厅

Source(s) of funding:

Science and Technology Department of Jiangsu Province

研究疾病:

输血相关疾病  

Target disease:

Transfusion related diseases

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

研究血型基因型配合性输血相对于表型配合性输血对患者近期及远期疗效的影响。  

Objectives of Study:

To study the influence of blood group genotype matching transfusion on the short-term and long-term effects of patients compared with phenotype matching transfusion.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

Exclusion criteria:

No

研究实施时间:

Study execute time:

From 2017-07-01 00:00:00 To 2020-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2018-06-01 00:00:00 To 2020-06-30 00:00:00

干预措施:

Interventions:

组别:

实验组

样本量:

50

Group:

Experimental group

Sample size:

干预措施:

血型基因型配合性输血

干预措施代码:

Intervention:

Blood group genotype matching transfusion

Intervention code:

组别:

对照组

样本量:

50

Group:

Control group

Sample size:

干预措施:

对症处理

干预措施代码:

Intervention:

Symptomatic treatment

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

江苏省人民医院 

单位级别:

三级甲等 

Institution
hospital:

Jiangsu Province Hospital

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

患者输血前、后24h的血常规

指标类型:

主要指标

Outcome:

Blood routine examination before and after blood transfusion in 24h for patients

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者输血后临床症状

指标类型:

主要指标

Outcome:

Clinical symptoms after transfusion

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者输血后反应

指标类型:

主要指标

Outcome:

Transfusion reaction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者输血后2周-3月新生抗体

指标类型:

主要指标

Outcome:

Newly-produced antibodies after transfution in 2 weeks to 3 months

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 120 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

N/A

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Data

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

分类采集、统计 保密原则

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Collection and Statistics Secrecy

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2018-04-18 20:32:09